Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10:1081 - 7; PMID: 22956807
   PubMed Web of Science ®Google Scholar
• Sandler HM, Mirhadi AJ. Radical radiotherapy for prostate cancer is the ‘only way to go’. [Williston Park] Oncology (Williston Park) 2009; 23:840 - 3; PMID: 19839425
   PubMed Web of Science ®Google Scholar
• Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365:107 - 18; http://dx.doi.org/10.1056/NEJMoa1012348; PMID: 21751904
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26:2497 - 504; http://dx.doi.org/10.1200/JCO.2007.14.9021; PMID: 18413638
   PubMed Web of Science ®Google Scholar
• Bannuru RR, Dvorak T, Obadan N, Yu WW, Patel K, Chung M, et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Ann Intern Med 2011; 155:171 - 8; PMID: 21646550
   PubMed Web of Science ®Google Scholar
• Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136:823 - 37; http://dx.doi.org/10.1016/j.cell.2009.02.024; PMID: 19269363
   PubMed Web of Science ®Google Scholar
• Pearl LH, Prodromou C. Structure and in vivo function of Hsp90. Curr Opin Struct Biol 2000; 10:46 - 51; http://dx.doi.org/10.1016/S0959-440X(99)00047-0; PMID: 10679459
   PubMed Web of Science ®Google Scholar
• Pratt WB. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 1998; 217:420 - 34; PMID: 9521088
   PubMed Web of Science ®Google Scholar
• Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006; 26:5A 3409 - 16; PMID: 17094460
   PubMed Web of Science ®Google Scholar
• Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19:575 - 86; http://dx.doi.org/10.1016/j.ccr.2011.04.008; PMID: 21575859
   PubMed Web of Science ®Google Scholar
• Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, Bristow RG. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 2011; 10:2218 - 32; http://dx.doi.org/10.4161/cc.10.13.16305; PMID: 21623170
   PubMed Web of Science ®Google Scholar
• Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 2008; 30:203 - 13; http://dx.doi.org/10.1016/j.molcel.2008.02.024; PMID: 18439899
   PubMed Web of Science ®Google Scholar
• Surucu B, Bozulic L, Hynx D, Parcellier A, Hemmings BA. In vivo analysis of protein kinase B (PKB)/Akt regulation in DNA-PKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis. J Biol Chem 2008; 283:30025 - 33; http://dx.doi.org/10.1074/jbc.M803053200; PMID: 18757368
   PubMed Web of Science ®Google Scholar
• Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995; 270:24585 - 8; http://dx.doi.org/10.1074/jbc.270.41.24585; PMID: 7592678
   PubMed Web of Science ®Google Scholar
• Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, et al. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res 2004; 10:8077 - 84; http://dx.doi.org/10.1158/1078-0432.CCR-04-1212; PMID: 15585643
   PubMed Web of Science ®Google Scholar
• Camphausen K, Tofilon PJ. Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res 2007; 13:4326 - 30; http://dx.doi.org/10.1158/1078-0432.CCR-07-0632; PMID: 17671112
   PubMed Web of Science ®Google Scholar
• Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999; 91:1940 - 9; http://dx.doi.org/10.1093/jnci/91.22.1940; PMID: 10564678
   PubMed Web of Science ®Google Scholar
• Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res 2003; 9:3749 - 55; PMID: 14506167
   PubMed Web of Science ®Google Scholar
• Dote H, Cerna D, Burgan WE, Camphausen K, Tofilon PJ. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res 2005; 65:6967 - 75; http://dx.doi.org/10.1158/0008-5472.CAN-05-1304; PMID: 16061682
   PubMed Web of Science ®Google Scholar
• Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer 2010; 126:1216 - 25; PMID: 19662650
   PubMed Web of Science ®Google Scholar
• Machida H, Nakajima S, Shikano N, Nishio J, Okada S, Asayama M, et al. Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis. Cancer Sci 2005; 96:911 - 7; http://dx.doi.org/10.1111/j.1349-7006.2005.00125.x; PMID: 16367912
   PubMed Web of Science ®Google Scholar
• Machida H, Matsumoto Y, Shirai M, Kubota N. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol 2003; 79:973 - 80; http://dx.doi.org/10.1080/09553000310001626135; PMID: 14713575
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Machida H, Kubota N. Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin. J Radiat Res 2005; 46:215 - 21; http://dx.doi.org/10.1269/jrr.46.215; PMID: 15988140
   PubMed Web of Science ®Google Scholar
• Moran DM, Gawlak G, Jayaprakash MS, Mayar S, Maki CG. Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene 2008; 27:5567 - 77; http://dx.doi.org/10.1038/onc.2008.172; PMID: 18504430
   PubMed Web of Science ®Google Scholar
• Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008; 68:2850 - 60; http://dx.doi.org/10.1158/0008-5472.CAN-07-5256; PMID: 18413753
   PubMed Web of Science ®Google Scholar
• Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008; 10:R33; http://dx.doi.org/10.1186/bcr1996; PMID: 18430202
   PubMed Web of Science ®Google Scholar
• Moser C, Lang SA, Hackl C, Wagner C, Scheiffert E, Schlitt HJ, et al. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res 2012; 32:2551 - 61; PMID: 22753713
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Andrulis M, Stühmer T, Müller E, Hofmann C, Steinbrunn T, et al. The PI3K/Akt signalling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 2012; PMID: 23065523
   PubMed Web of Science ®Google Scholar
• Ueno T, Tsukuda K, Toyooka S, Ando M, Takaoka M, Soh J, et al. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer 2012; 76:26 - 31; http://dx.doi.org/10.1016/j.lungcan.2011.09.011; PMID: 21996088
   PubMed Web of Science ®Google Scholar
• Zaidi S, McLaughlin M, Bhide SA, Eccles SA, Workman P, Nutting CM, et al. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One 2012; 7:e35436; http://dx.doi.org/10.1371/journal.pone.0035436; PMID: 22523597
   PubMed Web of Science ®Google Scholar
• Niewidok N, Wack LJ, Schiessl S, Stingl L, Katzer A, Polat B, et al. Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity. Transl Oncol 2012; 5:356 - 69; PMID: 23066444
   PubMed Web of Science ®Google Scholar
• Stingl L, Niewidok N, Müller N, Selle M, Djuzenova CS, Flentje M. Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α. Strahlenther Onkol 2012; 188:507 - 15; http://dx.doi.org/10.1007/s00066-012-0080-9; PMID: 22441439
   PubMed Web of Science ®Google Scholar
• Schilling D, Bayer C, Li W, Molls M, Vaupel P, Multhoff G. Radiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1α. PLoS One 2012; 7:e31110; http://dx.doi.org/10.1371/journal.pone.0031110; PMID: 22347438
   PubMed Web of Science ®Google Scholar
• Stingl L, Stühmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer 2010; 102:1578 - 91; http://dx.doi.org/10.1038/sj.bjc.6605683; PMID: 20502461
   PubMed Web of Science ®Google Scholar
• Terasima T, Tolmach LJ. Changes in x-ray sensitivity of HeLa cells during the division cycle. Nature 1961; 190:1210 - 1; http://dx.doi.org/10.1038/1901210a0; PMID: 13775960
   PubMed Web of Science ®Google Scholar
• Biade S, Stobbe CC, Chapman JD. The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles. Radiat Res 1997; 147:416 - 21; http://dx.doi.org/10.2307/3579497; PMID: 9092920
   PubMed Web of Science ®Google Scholar
• Ha K, Fiskus W, Rao R, Balusu R, Venkannagari S, Nalabothula NR, et al. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Mol Cancer Ther 2011; 10:1194 - 206; http://dx.doi.org/10.1158/1535-7163.MCT-11-0094; PMID: 21566061
   PubMed Web of Science ®Google Scholar
• Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, et al, Australian Prostate Cancer BioResource. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 2012; 18:3562 - 70; http://dx.doi.org/10.1158/1078-0432.CCR-12-0782; PMID: 22573351
   PubMed Web of Science ®Google Scholar
• Wang X, Ma Z, Xiao Z, Liu H, Dou Z, Feng X, et al. Chk1 knockdown confers radiosensitization in prostate cancer stem cells. Oncol Rep 2012; 28:2247 - 54; PMID: 23027394
   PubMed Web of Science ®Google Scholar
• Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003; 63:8984 - 95; PMID: 14695217
   PubMed Web of Science ®Google Scholar
• Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 2005; 65:11565 - 71; http://dx.doi.org/10.1158/0008-5472.CAN-05-3441; PMID: 16357166
   PubMed Web of Science ®Google Scholar
• Wong J, Armour E, Kazanzides P, Iordachita I, Tryggestad E, Deng H, et al. High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities. Int J Radiat Oncol Biol Phys 2008; 71:1591 - 9; http://dx.doi.org/10.1016/j.ijrobp.2008.04.025; PMID: 18640502
   PubMed Web of Science ®Google Scholar
• Fertil B, Dertinger H, Courdi A, Malaise EP. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 1984; 99:73 - 84; http://dx.doi.org/10.2307/3576448; PMID: 6739728
   PubMed Web of Science ®Google Scholar
• Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008; 14:5142 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-07-4072; PMID: 18698032
   PubMed Web of Science ®Google Scholar